Sunday 15 November 2026
Export DYAI’s income statement to Excel — free account
Dyadic International Inc.
DYAIDyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.
- Revenue
- −61.4%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +0.80%
Quarter to September 2026, against a year earlier
0.33
0.02
−5.71%
Follow DYAI
Alert me
Dyadic International Inc. (DYAI) news
The news and the share price important stories, numbered as below
Stories the last two months, newest first
More headlines
- Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026 GlobeNewswire
- How One Biotech Stock Is Trying To Reduce A Big Hidden Cost Simply Wall St.
- iAccess Alpha Virtual Best Ideas Fall Investment Conference Begins Today with Updated Presentation Schedule
- iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
- Q3 Virtual Investor Summit Presentations Now Available On Demand
- Dyadic International (DYAI) Q2 2026 Earnings Call Transcript The Motley Fool transcript
- DYAI: Second Quarter Results
- Dyadic International, Inc. Q2 2026 Earnings Call Summary Moby
- Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
- Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ... transcript
- Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
- Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
- Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026
- Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
- Dyadic Announces Continued Listing on the Nasdaq Capital Market
- Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
- Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program GlobeNewswire
- Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
- Dyadic Expands IP Protection and Business Development Activities in Japan
- An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets TMX Newsfile
- Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
- Dyadic (DYAI) Q1 2026 Earnings Call Transcript The Motley Fool transcript
- Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development GlobeNewswire
- Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 GlobeNewswire